Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
In recent years, the familiar symptoms of the flu might kick us into reaching for at-home testing kits. But on the eve of the ...
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, ...
The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback